Migraine diagnosis and pathophysiology

CONTINUUM Lifelong Learning in Neurology

Volumn 18, Issue 4, 2012, Pages 753-763

  Ward, Thomas N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; ERGOTAMINE; ERGOTAMINE TARTRATE; ESTROGEN; METHYSERGIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; SUMATRIPTAN; TOPIRAMATE; VALPROIC ACID;

BLOOD VESSEL; BRAIN ARTERY; DISABILITY; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DURA MATER; EAR; EYE; FACE; FACIAL NERVE; FRONTAL LOBE; GLOSSOPHARYNGEAL NERVE; HEADACHE; HEMIPARESIS; HEMIPLEGIA; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; NECK MUSCLE; NERVE ROOT; NEUROIMAGING; NONHUMAN; OCULOMOTOR NERVE; OROPHARYNX; PAIN ASSESSMENT; PARANASAL SINUS; PATHOPHYSIOLOGY; PHONOPHOBIA; PHOTOPHOBIA; REVIEW; SCALP; SINUS VENOSUS; SPREADING CORTICAL DEPRESSION; TEMPORAL LOBE; TENDON; TRANSCRANIAL MAGNETIC STIMULATION; TRIGEMINAL NERVE; TROCHLEAR NERVE; VAGUS NERVE; VASOCONSTRICTION; VOMITING;

ADULT; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MIGRAINE DISORDERS; NEURAL PATHWAYS; NEUROIMAGING;

EID: 84864866339     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000418640.07405.31     Document Type: Review

References (38)

1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004;24(suppl 1) 9-160.
2. International Headache Society. www.ihs-headache.org. Accessed May 4, 2012.
3. Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headaches. J Neurol Neurosurg Psychiatry 1960;23 23-32.
4. Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psychiatry 1941;46(2) 331-339.
5. Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944;7(6) 359-390.
6. Stewart WF, Wood C, Reed ML, et al. Cumulative lifetime migraine incidence in women and men. Cephalalgia 2008;28(11) 1170-1178.
7. Charles A. Advances in the basic and clinical science of migraine. Ann Neurol 2009;65(5) 491-498.
8. Ward TN, Levin M. Diagnosis and pathophysiology of migraine. Expert Rev Neurother 2004;4(3) 383-390. (Pubitemid 38607905)
9. Packard RC, Ham LP. Pathogenesis of posttraumatic headache and migraine a common headache pathway? Headache 1997;37(3) 142-152. (Pubitemid 27167345)
10. Valenti S, Fazzuoli L, Giusti M. Circulating nitric oxide levels increase after anti-androgenic treatment in male-to-female transsexuals. J Endocrinol Invest 2003;26(6) 522-526. (Pubitemid 36998700)
11. Lipton RB, Silberstein SD. Why study the comorbidity of migraine? Neurology 1994;44(10 suppl 7) S4YS5.
12. Goadsby PJ. The vascular theory of migraineVa great story wrecked by the facts. Brain 2009;132(pt 1) 6-7.
13. Graham JR, Wolff HG. Mechanisms of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938;39(4) 737-763.
14. Peroutka SJ. The pharmacology of current antimigraine drugs. Headache 1990;30(suppl 1) 5-11; discussion 24-28.
15. Goadsby PJ. Serotonin receptor ligands treatments of acute migraine and cluster headache. Handb Exp Pharmacol 2007;(177) 129-143.
16. Dalkara T, Zervas NT, Moskowitz MA. From spreading depression to the trigeminovascular system. Neurol Sci 2006;27(suppl 2) S86YS90. (Pubitemid 44390119)
17. Levin M. Head pain anatomy and physiology. In Levin M, ed. Comprehensive review of headache medicine. Oxford, UK Oxford University Press, 2008 3-19.
18. Goadsby PJ, Lipton RB, Ferrari MD. MigraineVcurrent understanding and treatment. N Engl J Med 2002;346(4) 257-270.
19. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain a race against the development of central sensitization. Ann Neurol 2004;55(1) 27-36. (Pubitemid 38067358)
20. Ashkenazi A, Sholtzow M, Shaw JW, et al. Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia 2007; 27(2) 111-117. (Pubitemid 46169435)
21. Woods RP, Iacoboni M, Mazziotta JC. Brief report bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994;331(25) 1689-1692. (Pubitemid 24373622)
22. Shapiro RE. Pathophysiology and genetics of migraine and cluster headache. In Levin M, ed. Comprehensive review of headache medicine. Oxford, UK Oxford University Press, 2008 21-38.
23. Ramadan NM, Halvorson H, VandeLinde A, et al. Low brain magnesium in migraine. Headache 1989;29(7) 416-419. (Pubitemid 20334114)
24. van den Maagdenberg AM, Pietrobon D, Pizzorusso T, et al. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 2004;41(5) 701-710. (Pubitemid 38326833)
25. Brennan KC, Romero-Reyes M, Ló pez Valdé z HE, et al. Reduced threshold for cortical spreading depression in female mice. Ann Neurol 2007;61(6) 603-606. (Pubitemid 47068143)
26. Aurora SK, Welch KM, Al-Sayed F. The threshold for phosphenes is lower in migraine. Cephalalgia 2003;23(4) 258-263. (Pubitemid 36577942)
27. Wang W, Schoenen J. Interictal potentiation of passive oddball auditory event-related potentials in migraine. Cephalalgia 1998;18(5) 261-265; discussion 241. (Pubitemid 28322621)
28. Goadsby PJ. Pathophysiology of migraine. Neurol Clin 2009;27(2) 335-360.
29. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372(9656) 2115-2123.
30. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology 1960;10 107-111.
31. Humphrey PPA, Feniuk W, Perren MJ. Anti-migraine drugs in development advances in serotonin receptor pharmacology. Headache 1990; 30(suppl 1) 12-16; discussion 24-28. (Pubitemid 20321427)
32. Curran DA, Hinterberger H, Lance JW. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 1965;88(5) 997-1010.
33. Ayata C,Hongwei J, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006;59(4) 652-661.
34. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1(7) 658-660.
35. Kruit MC, van Buchem MA, Launer LJ, et al. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation the population-based MRI CAMERA study. Cephalalgia 2010;30(2) 129-136.
36. Young VG, Halliday GM, Kril JJ. Neuropathologic correlates of white matter hyperintensities. Neurology 2008;71(11) 804-811.
37. Rozen TD. Vanishing cerebellar infarcts in a migraine patient. Cephalalgia 2007;27(6) 557-560. (Pubitemid 46848915)
38. Dowson A, Mullen MJ, Peatfield R, et al. Migraine Intervention With STARFlex Technology MIST) trial a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 2008;117(11) 1397-1404. (Pubitemid 351501492)